2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1422

Identifying Generic and Specific Patients’ Perspectives on Disease- and Treatment-Related Issues in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: A Qualitative Concept Mapping Study
Abstract Number: 1423

Using Self-Reported Patient Experiences to Evaluate Patient Reported Outcomes (PRO) Instruments: Learnings from Digital Patient Communities in Psoriatic Arthritis
Abstract Number: 1424

Acceptability of a Connected Activity Tracker in 92 Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA): A 3-Months Study
Abstract Number: 1425

Validation of a Patient Reported Experience Measure (PREM) in Patients with Axial Spondyloarthropathies (AxSpA)
Abstract Number: 1426

Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis
Abstract Number: 1427

The Importance of Outcome Measures in Ankylosing Spondylitis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Cohort
Abstract Number: 1428

Patient Attitudes Towards Being Prescribed Biosimilars in Inflammatory Autoimmune Diseases in Germany
Abstract Number: 1429

Patient-Reported Outcomes Measures and Economical Burden of Patients with Ankylosing Spondylitis in a Chinese Prospective Cohort with Smart Management System for Spondyloarthritis
Abstract Number: 1430

Adherence to the International Consensus Quality Indicators for Longitudinal Health Maintenance and Preventative Care in a Pediatric Rheumatology Clinic
Abstract Number: 1431

Estimates of Global Status By Physicians and Patients Are More Likely to be Discordant in Osteoarthritis Than in Rheumatoid Arthritis
Abstract Number: 1432

The EULAR Systemic Sclerosis Impact of Disease Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis Under Development
Abstract Number: 1433

Self-Perception Reporting to Healthcare Professionals: Do Individuals with Systemic Sclerosis Report Quality of Life Changes Accurately?
Abstract Number: 1434

Effect of Systemic and Local Inflammation on the Insulin Resistance and Glucose/Lipid Metabolism in Rheumatoid Arthritis: Humans and CIA Mouse Model
Abstract Number: 1435

KCa1.1 Potassium Channels Are a Novel Therapeutic Target on Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Abstract Number: 1436

TAS8274, a Highly Selective Janus Kinase 3 Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].